Project Grant F31DA063346

Award Date 10/10/25
Completion Date 4/30/28
Dollars Obligated $93K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $246,000.00 to The Trustees of Princeton University to investigate the brain mechanisms underlying the therapeutic potential of psilocybin. The research aims to: 1) examine the accelerated acquisition of motivated behavior and task performance after psilocybin administration, and 2) identify the cellular and brain-wide substrates driving...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $6,489,450.00 to New York University to evaluate psilocybin as an adjunctive treatment for opioid use disorder (OUD) in methadone-maintained patients who continue to use illicit opioids. The study will recruit 240 participants from opioid treatment programs in New York and New Mexico, and will provide psilocybin treatment implemented as...
The National Institute of Mental Health (NIMH) awarded a $679,118 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of California, Santa Cruz (UCSC) to study the cellular and circuit mechanisms underlying the long-lasting therapeutic effects of the psychedelic drug psilocybin in the stressed brain. The project aims to determine how psilocybin affects synaptic plasticity, cortical functional networks, and the representation of behavioral variables in the stressed...
This federal Project Grant award for $708,511 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a mechanistic trial to elucidate the effects of psilocybin on neural activity in individuals with alcohol use disorder (AUD). The study aims to evaluate the impacts of high-dose versus low-dose psilocybin on AUD patients' neural response to negative affective stimuli and alcohol cues, as well as subsequent drinking...
This federal Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $643,019 to Virginia Commonwealth University (VCU) to explore the potential efficacy and safety of psilocybin as a treatment for cocaine use disorder (COCUD). The award will fund a proof-of-concept randomized controlled trial to evaluate the treatment effects of psilocybin combined with psychedelic integrative therapy and...
This $1,255,890 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, supports research at Cornell University to investigate the role of cortical GABAergic interneurons in the effects of the psychedelic drug psilocybin. The key objectives are to: 1) use cell type-specific electrophysiology to measure how the three major subtypes of GABAergic interneurons in the mouse medial frontal cortex respond to psilocybin...
This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the federal Research and Training in Complementary and Integrative Health program (CFDA 93.213), will fund a feasibility clinical trial to develop and evaluate a Psilocybin-Assisted Cognitive Behavioral Therapy (PA-CBT) protocol for treating major depressive disorder. The $236,250 award, granted on December 17, 2024, supports a 3-year study to refine and optimize the PA-CBT approach, and...
This Project Grant award of $216,678 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a research project titled "MENTORING CLINICAL INVESTIGATORS IN PSYCHEDELIC-ASSISTED THERAPY FOR HIV (MENTOR-PATH)". The award, effective August 1, 2025 through July 31, 2030, will support the Principal Investigator, Dr. Parya Saberi, in (1) providing mentorship to early career trainees from diverse backgrounds in areas...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding research at the University of Oregon to investigate the polypharmacology and psychoplastogenic effects of psychedelic drugs using the C. elegans model organism. The overarching goal is to determine how representative psychedelic compounds, which primarily activate serotonin receptors, influence behavior and neuroplasticity in this invertebrate...
The National Institutes of Health's National Institute on Drug Abuse awarded New York University School of Medicine a $1,446,310 Project Grant under the Drug Abuse and Addiction Research Programs to adapt an evidence-based posttraumatic stress disorder intervention for polysubstance use populations receiving treatment for opioid use disorder. Specifically, the award will support adapting an existing trauma-focused therapy, Skills Training in Affective and Interpersonal Regulation with...

THERAPEUTIC POTENTIAL OF PSILOCYBIN ON STRESS-CUED REINSTATEMENT - PROJECT SUMMARY OPIOID USE DISORDER (OUD) AND POST-TRAUMATIC STRESS DISORDER (PTSD) ARE HIGHLY COMORBID AND MUTUALLY EXACERBATING. THERE IS A CRITICAL UNMET NEED FOR PHARMACOTHERAPEUTICS TARGETING STRESS-PRECIPITATED RELAPSE, AS STRESS-CONDITIONED STIMULI ARE A MAJOR DRIVER OF RELAPSE IN COMORBID PATIENTS. CLASSICAL PSYCHEDELICS LIKE PSILOCYBIN ARE APPEALING CANDIDATES AS THERAPEUTICS FOR OUD, AS THEY DO NOT LEAD TO PHYSICAL DEPENDENCE AND DEMONSTRATE PROMISING POTENTIAL IN REDUCING STRESS AND ADDICTIVE BEHAVIORS IN HUMANS. THESE EFFECTS APPEAR TO BE LONG-LASTING FROM ONE TO FEW TREATMENTS, SUGGESTING ADAPTATION TO NEURAL CIRCUITS AFFECTED BY CHRONIC STRESS AND SUBSTANCE USE. DESPITE PROMISING CLINICAL EVIDENCE SUGGESTING THE EFFICACY OF PSYCHEDELICS IN THE TREATMENT OF STRESS AND SUBSTANCE USE DISORDERS, THERE IS A CRITICAL GAP IN THE PRECLINICAL PROFILING OF PSYCHEDELICS IN OUD MODELS. UNDERSTANDING THE NEURAL MECHANISMS UNDERLYING THE THERAPEUTIC EFFECT OF THESE COMPOUNDS IS NECESSARY FOR FUTURE DEVELOPMENT OF NOVEL OUD THERAPEUTICS WITH REDUCED HALLUCINOGENIC SIDE EFFECTS. WE HAVE DEVELOPED A NOVEL MOUSE MODEL FOR STUDYING RELAPSE INDUCED BY CUES ASSOCIATED WITH PRIOR STRESSFUL LIFE EVENTS. MY PRELIMINARY DATA FROM THE SMITH LABORATORY DEMONSTRATE THAT THE PSYCHEDELIC 2,5,DIMETHOXY-4-IODOAMPHETAMINE (DOI) BLOCKS STRESS-CUED REINSTATEMENT TO HEROIN IN MICE. WE IDENTIFIED THE ANTERIOR INSULAR CORTEX (AIC) AS A BRAIN STRUCTURE THAT MAY MEDIATE THE INTERACTION BETWEEN PSYCHEDELICS, STRESS, AND OUD, AND FIND THAT DOI REDUCES REINSTATEMENT-INDUCED C-FOS IN THE AIC. WE PROPOSE THAT PSYCHEDELIC- INDUCED PLASTICITY PROMOTES LASTING ADAPTATIONS TO CIRCUITRY AFFECTED BY STRESS AND HEROIN SEEKING, RESULTING IN AN ATTENUATION OF STRESS-CUED HEROIN SEEKING. AIM 1 WILL IDENTIFY THE WHOLE-BRAIN PATTERN OF NEURONAL ACTIVITY AND BEHAVIORAL EFFECT OF PSILOCYBIN ON STRESS-CUED REINSTATEMENT TO HEROIN. USING CELL-TYPE SPECIFIC CIRCUIT MANIPULATION VIA CHEMOGENETICS, WE WILL GAIN VALUABLE INSIGHT INTO THE NECESSITY OF AIC 5HT2AR IN MODULATING STRESS-CUED REINSTATEMENT TO HEROIN. UNDERSTANDING THE ROLE OF THE 5HT2AR, WHICH MEDIATES HALLUCINOGENIC ACTIVITY OF PSYCHEDELICS, IN THE THERAPEUTIC EFFECTS OF PSYCHEDELICS WILL PROVIDE CRITICAL INFORMATION TO STEER DRUG DISCOVERY EFFORTS AIMING TO TREAT STRESS AND SUBSTANCE USE DISORDERS WITH SEROTONIN AGONISTS. AIM 2 WILL USE FIBER PHOTOMETRY TO RECORD AIC CALCIUM DYNAMICS DURING A STRESSFUL EXPERIENCE AND RE-EXPOSURE TO STRESS-CUE, AND DETERMINE HOW TREATMENT WITH PSILOCYBIN IMPACTS THESE RESPONSES. TOGETHER, THESE EXPERIMENTS SEEK TO ELUCIDATE CIRCUIT MECHANISMS UNDERLYING THE EFFECT OF PSILOCYBIN ON STRESS-INDUCED HEROIN SEEKING BEHAVIORS. THIS STUDY WILL BE CONDUCTED AT THE MEDICAL UNIVERSITY OF SOUTH CAROLINA, A LEADING CENTER IN THE FIELD OF ADDICTION NEUROSCIENCE. UNDER THE MENTORSHIP OF DRS. ALEXANDER SMITH AND CHRISTOPHER COWAN, I WILL RECEIVE TRAINING IN RODENT INTRAVENOUS DRUG SELF-ADMINISTRATION, WHOLE BRAIN C-FOS MAPPING, CHEMOGENETICS, IN VIVO RECORDING OF NEURAL ACTIVITY WITH FIBER PHOTOMETRY, AND COMPUTATIONAL TOOLS FOR DATA ANALYSIS.

Posted 4/11/25